Widely used:Recently Viewed
Clear All
$25 Mln
--
0.29
--
0
-66.63 %
--
0 %
2.24
-1741211
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bolt Biotherapeutics (BOLT)
| -42.41 | -5.12 | -12.54 | -33.51 | -63.61 | -- | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
Bolt Biotherapeutics (BOLT)
| -13.85 | -73.47 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$24.68 Mln
$11.17 Mln
$0.00 Mln
$73.70 Mln
$18.89 Mln
High
$0.55 - 1.56
38,264,800
NASDAQ: BOLT
Redwood City, CA
https://www.boltbio.com
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of... patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. Read more
The total asset value of Bolt Biotherapeutics (BOLT) stood at $ 142 Mln as on 30-Jun-24
The share price of Bolt Biotherapeutics (BOLT) is $0.65 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Bolt Biotherapeutics (BOLT) has given a return of -63.61% in the last 3 years.
Bolt Biotherapeutics (BOLT) has a market capitalisation of $ 25 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bolt Biotherapeutics (BOLT) is 0.29 times as on 04-Oct-2024, a 91% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Bolt Biotherapeutics (BOLT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bolt Biotherapeutics (BOLT) and enter the required number of quantities and click on buy to purchase the shares of Bolt Biotherapeutics (BOLT).
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
The CEO & director of Dr. Randall C. Schatzman Ph.D.. is Bolt Biotherapeutics (BOLT), and CFO & Sr. VP is Dr. Randall C. Schatzman Ph.D..
There is no promoter pledging in Bolt Biotherapeutics (BOLT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Bolt Biotherapeutics (BOLT) | Ratios |
|---|---|
|
Return on equity(%)
|
-66.63
|
|
Operating margin(%)
|
-667.52
|
|
Net Margin(%)
|
-592.57
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Bolt Biotherapeutics (BOLT) was $0 Mln.
$0.01
